AMCIL Limited (AMH) Earnings Call Transcript & Summary

January 22, 2026

Australian Securities Exchange AU Financials Capital Markets earnings 50 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, and thanks for joining us for the AMCIL Half Year Financial Results Briefing. <<operator_script>> At this point I'll pass things over to the Managing Director of AMCIL, Mr. Mark Freeman. Thanks very much. Over to you.

Robert Freeman

executive
#2

Alright, good afternoon to all of you. My name is Mark Freeman, and I serve as CEO and Managing Director of AMCIL Limited. I also hold the role of Portfolio Manager at the company, and I welcome you to this briefing on the half year result. First, I want to acknowledge the Traditional owners and custodians of all the lands on which we are gathered today, and I pay my respects to the Elders past, present, and emerging. With me today on the webinar are Jaye Guy, an investment analyst; and Gilbert Battistella; Andrew Porter, our CFO; Matthew Rowe, our Company Secretary; Geoff Driver, our General Manager of Business Development; and Suzanne Harding, our Business Development Manager. Before we begin the presentation, a few housekeeping notes about this webinar. This briefing draws on the material available on the company's website. If you are accessing the presentation via the webcast on your computer, the slides will change automatically. Lastly, please be aware that after the presentation, there will be time for questions and answers. You can submit a question through the webcast using the tab at the bottom of the screen. I'll now go to Slide 2, our disclaimer, which notes that we're here to talk about the company. We're not providing any advice as such.

Robert Freeman

executive
#3

Turning to the following slide, this is simply the agenda. I'll speak briefly about how we go about things. Our CFO, Andrew Porter, will summarise the half year, and then I'll take you through the remaining slides in the presentation. As a reminder for everybody, our purpose and the attributes of AMCIL: clearly, this is a concentrated portfolio. It's a high conviction fund. Interests are aligned, costs are relatively low. No performance fees go to any external party, and there's meaningful equity ownership among directors and staff. So in that sense, we're all in it together. We aim for low turnover. Trading isn't what we do. We recognise that, at the end of the day, tax takes a significant toll on returns. So our aim is to invest for the longer term in quality companies. On to the next slide. We've discussed this slide for quite a few years now, and we want our approach to stay consistent. Specifically, we concentrate on what we term higher-quality companies, where a longer-term view is possible. We look for businesses possessing unique assets that are difficult to replicate, or companies holding a leadership position, along with a sustainable competitive advantage.

Robert Freeman

executive
#4

So in that sense, we talk about a business moat. We know there are companies affected by outside forces that can hit the business. Our preference is to hold companies with strong balance sheets. We favor businesses whose long-term earnings streams are more consistent. We like firms led by effective, passionate management teams that have ownership alignment. And the reason all of these factors matter is that, taken together, they produce a sustainable long-term competitive advantage, which generally leads to a high return on capital, makes reinvestment possible to drive growth, gives the ability to capture market share, strengthens their position, and ultimately delivers shareholder value through growing profits, generally organically. And as noted there, growing profits over the long term is what we aim to achieve, because ultimately share prices follow profits. And we want to buy and add to positions when value shows up. So we want to be a value investor around quality businesses. We will exit companies when we -- when they stop fitting those frameworks. I'll quickly hand over to Andrew Porter to discuss some of the numbers, and then I'll get into the portfolio and the market.

Andrew J. Porter

executive
#5

Thanks, Mark, and good afternoon, everyone. A lot of you will recognize these 4 boxes that we review every period. For the half year, profit came in at $4.1 million, which is actually higher than the profit recorded in the same period a year ago. Dividends were broadly unchanged. What's different is the contribution from options trading in a rising market — option prices are a bit higher, and we managed to generate just under $500,000 from option trading this year, while in the prior year we had a small loss on options, since we held a trading portfolio that carried an unrealized loss at that point. Those are the main factors behind the increase in profit. The interim dividend is unchanged. The Board has announced $0.01. Of course, when it comes to the final, that's when the Board will review the overall status of the factor credits, including any realized gains. But the interim dividend itself comes in at $0.01. The management expense ratio, the box in the top right-hand corner, is the cost — the ratio of running the company, the expenses incurred — 0.43%, which works out to $0.43 for every $100 invested.

Andrew J. Porter

executive
#6

At the half year, it usually comes in somewhat lower than usual, because of reduced cost from AICS tied to incentives not vesting. For 2024 it's 0.53%. It can move around considerably, and that's the reason we disclose it but at the half year we don't give it the same attention as at the full year. The 0.43% isn't out of the ordinary. In 2023, for example, it was 0.46%. Portfolio, $358 million. And as Mark said, he'll come in later and talk about the portfolio and how it performed. On the next slide — this is something we publish alongside the NTA each month. We believe it matters that shareholders grasp what they're purchasing. At the end of December, for instance, are they purchasing $112 $1.12 of assets for $1.01, or, as in '21 and '22, purchasing shares at a premium — that is, paying more for the shares than what lies beneath them. So the discount was roughly 10% at the end of December 2025. One point I'd raise, since we've had this question before: ETFs arrived in the Australian market on a large scale in 2017 and 2018.

Andrew J. Porter

executive
#7

They’ve been out there for a while now. ETFs, of course, work with a different structure. With those, for example, you won’t get dividend consistency. So yes, ETF growth has occurred, but they aren’t really equivalent to LICs. And it’s worth pointing out, in fact, that in December 2024 — this time last year — just as a reminder to shareholders, the 6-month performance, 1-year performance, 3-year performance — sorry, 5-year performance and 10-year performance, not the 3-year performance — were all comfortably ahead of the index. The discount was in fact much higher than it is today. So the discount isn’t something we can control, but over the last 6 months we have been buying back shares in an attempt to ensure that we weren’t — it was actually — it makes economic sense if you can buy shares back at a discount when they’ve been issued. So that neutralized the DRP. And as Mark introduced, we’ve taken on Suzanne, whose roles include talking about the benefits of LICs and AMCIL in particular. And with that, I’ll pass back to Mark.

Robert Freeman

executive
#8

Alright, thank you, Andrew. So continuing through the slides, here are a few of the conditions we're observing. Obviously, significant geopolitical friction exists around the globe, and that's driving plenty of rotation among subsectors in equity markets, which we'll get to shortly. Markets, in our view, still look somewhat full on valuation. They aren't extreme, I'd say, just full. That said, economic conditions have probably held up better than we had anticipated. Tariffs keep wreaking chaos on economies and on the outlook. Considerable political strain is emanating from the U.S. We've had a resources rally, especially in gold and silver prices — among the strongest gold gains witnessed in decades — and more lately, worries the market holds about AI and what it might mean for stocks down the road. And once more, we'll address that shortly. Looking at some longer-term valuation metrics, the P/E for the Australian market remains elevated, while the dividend yield sits essentially at record lows. And turning to the U.S. market, similar fundamentals show up: P/Es that are very high, and dividend yields that are very low.

Robert Freeman

executive
#9

If you look at the U.S. market, the difference is perhaps that EPS growth there has been very strong—much stronger than in Australia—which could justify a higher multiple, and return on equity from the U.S. market has also been rising. And again, that is much higher than what we've seen come out of the Australian market. So if we then turn to the portfolio and look at returns, clearly this has been a very disappointing year for the portfolio. As Andrew stated, given that we sat here 1 year ago seeing outperformance across 1, 5 and 10 years. A lot has changed in 1 year. We haven't changed our style approach. There have just been significant movements within the sectors we focus on, and I'll come to that shortly. Interestingly, when I look at perhaps the 3-year number, that underperformance over that period is more than accounted for simply by having our -- we've got no exposure to banks. We see them as fully valued and gold. As I said, those 2 factors alone, having strategic positioning around those 2 sectors, more than covers the underperformance over 3 years, and we'll come to that shortly. If you look at the next slide, particularly on the left, you can see over 12 months, health care and information technology, home to several structured compounders.

Robert Freeman

executive
#10

We favor businesses that compound because they let us adopt a longer-term perspective and act as a longer-term investor. As I mentioned, we always keep the tax impact in mind. Then with materials, as you can see, they're up more than 35%. The bulk of that comes from mid- and small-cap resources, where gains in those sectors have ranged anywhere from 70% to 100%. So it's a very unusual period in our markets. Looking at just a couple of those sectors that have really hurt us, certainly across that 3-year stretch — we don't hold any of the major banks right now. That doesn't mean we never will, but we simply believe they remain fully priced. There's been a bit of a pullback in CBA more recently. In our view, CBA is an excellent company. We'd love to own it. It fits our process, yet we still find some of the bank valuations pretty extreme. But this move in the banks, this P/E re-rating, as I said, has been a key driver of underperformance over 3 years. And then, moving to the next slide, the other key area of underperformance across 3 years is not having owned gold.

Robert Freeman

executive
#11

Opening the presentation, I want to reiterate what I've said for 3 years now: our framework has centered on being quality structured compounders while steering clear of everything else. Right now, we have plainly been missing out on this segment of the market. Looking at where the price stands today, it appears quite extreme — probably comparable to other extremes around 1977, around 2008, and to some degree in 2017. There are, of course, plenty of reasons behind that price move. Our preference is to hold productive assets. Gold is volatile by nature. Still, a great deal of money has clearly been made there lately, yet we have stayed fairly consistent in stating that our focus is on businesses we regard as long-term structured compounders. I'm quite curious to see how this chart looks in the coming few years, since history shows a pattern emerging once you reach these fairly heavy extremes. Moving to the next slide, it's somewhat busier and may be — it could be hard to read, but this is analysis from Macquarie examining how particular investing styles have performed over time.

Robert Freeman

executive
#12

We've gone down the left-hand column to a group we call quality compounders. These are companies with a strong market position that can keep growing for many years. Over on the right-hand side, the relative performance is shown. And that right-hand column, I believe, dates back to 1998. So over the long run, putting money into quality compounders and holding them is an excellent way to beat the market. But if you look back a couple of columns, the part we circled in red, that's how that did during the last calendar year. So as you can see, it was an absolutely dreadful year to own quality compounding businesses — likely among the worst ever, given how they derated. And right below that, you can see it's really the outcome of money draining out of that part of the market and moving into the resource segment. So the last calendar year has been among the best years to hold loss-making businesses, and many of those are start-up and junior mining companies. Over the long run, though, loss-making businesses are not somewhere you want to be, but they've certainly been a great shorter-term place to make money. So we've had, I suppose, a perfect storm working against us.

Robert Freeman

executive
#13

We are most overweight in quality compounders. And as I mentioned, it's one of the worst years I can remember in history. Meanwhile, we're underweight loss-making businesses and junior mining companies, which have been the strongest segment of the market, and that is what has driven the performance gap across 12 months. Our current plan is to remain committed to our frameworks and our processes. And the best way to grasp that is by examining stocks, which we'll do shortly. Moving to the following slide. So we've sorted those into buckets. So I've discussed and left notable share price weakness across quality growth companies. In most cases, though, the long-term thesis remains intact. There have been a few cyclical headwinds affecting a couple of our stocks; Reece and James Hardie also suffered from an unfortunate transaction. I don't object to the business they acquired, but the manner in which they did it, I believe, has transferred value across to the company they've acquired. And then banks and gold resources, and I've addressed that on earlier slides, their strength. So if we consider some of the stocks, you can see some of the numbers here. I've begun with some stocks that we have encountered some issues with.

Robert Freeman

executive
#14

WiseTech has pulled back quite a bit. Our holding in it has been trimmed. A position in the stock has been kept. It is a fascinating business. Clearly, there has been plenty of negative press and governance concerns. We have definitely been sharing our views with the company regarding those troubling matters. On the bright side, the business keeps expanding and is turning into the operating system for the largest transport and logistics firms globally. And so far, we have not observed any shift in that regard. An acquisition was made by them, and it will slow the pace of earnings growth. The rationale behind the deal is clear to me, yet it has led people to rethink EPS growth and, as a result, the multiple the stock trades at. This business is complicated. There is worry across all software companies about what AI could do — namely, AI's capacity to write code that replicates products like these. But firms such as WiseTech and even Xero are in fact making heavy use of AI to strengthen their moats. Consider WiseTech: they rely on a great deal of proprietary data collected over many years to help operate their processes and systems. AI is unable to replicate that. So we have chosen, in this portfolio at least, to keep a position, given that if they make it through this stretch, the software they have is truly one of a kind and must be embedded within the biggest logistics companies worldwide.

Robert Freeman

executive
#15

It ought to keep delivering solid earnings growth, though obviously right now it's deeply unpopular. The market isn't fond of it. In that kind of climate, I'm hesitant to offload it. So we're watching to see how things develop, while we keep providing input to the company regarding certain enhancements we'd like the business to make. Xero, once again, is another business that made an acquisition to accelerate its development. They believed they had to strengthen the product suite in order to expand in the U.S. They're pouring a lot of investment into trying to establish a position in the U.S. The company has delivered on every commitment it made. More recently, I think the largest worry, again, is what AI could potentially do. I'm probably still in the camp holding that this isn't a costly product for the end user. For those who use it, such as WiseTech, it's mission-critical software. You can't afford for this product to fail. Again, Xero is investing heavily in AI to strengthen their moat, yet the stock remains under considerable pressure. Each of those two holdings sits at roughly 1% of the portfolio. Reece has endured a downturn in the U.S. for those who track the U.S.

Robert Freeman

executive
#16

The housing market moves in cycles, and right now you're sitting at a cyclical trough. My sense is the company gets that, given how aggressively they've been repurchasing shares in the market lately. I mentioned Hardie's — the way they structured that deal was disappointing. We've conveyed our thoughts on it to the company. Still, at the end of the day, their fiber cement operation remains highly strategic and suits our process. The business they acquired also holds a leading position in the decking market this time around. There's merit in the two combining. I simply dislike how they went about it. But now that it's done, our position is smaller. The balance sheet doesn't please us. Yet if they keep performing well over the coming couple of years, that balance sheet will strengthen considerably. And beyond that, the assets are genuinely strong. CSL has likely been the biggest letdown, since we held a large stake there, and clearly our view was overly optimistic — that was a mistake. The market has been reassessing, really around earnings growth.

Robert Freeman

executive
#17

Twelve months back, the market anticipated EPS growth in the teens. At this point, it's likely high single digit. That has driven a meaningful compression in the P/E multiple. When you examine this company's long-term EPS growth, it has continued expanding, though not at mid-teens — more like high single digits. Our view is that they ought to be able to keep that up. And the P/E has reached a level where a number of what I'd describe as deep value managers have begun purchasing the stock. So for now we're going to stay with it, provided we keep seeing profit growth come through. But that particular one has not worked out well for us. And IDP, I suppose, has been affected by the sector swinging from peak to trough as a result of government policy. They remain the leading player in that sector. The industry is still very fragmented. There are indications of improvement in Australia and the U.K. It's a small position in the portfolio, and given that leadership position they hold, we're going to keep holding it. So there are some problems surrounding each of those, yet there are also solid reasons why they remain structured compounders going forward.

Robert Freeman

executive
#18

So we still hold positions in those names. Moving to the next slide, there are quite a few stocks listed here. You can see just how much quality compounding fell out of favor. You can see the declines in share price. For these companies, our long-term investment thesis hasn't changed at all. We continue to view them as well-run businesses. They hold leadership positions in what they do. There's every reason for them to grow earnings and profits over the long term. A lot of them carry net cash on the balance sheet, yet the share price move across the 1 year has been quite extreme on the downside. And thinking about it, let me just highlight a few, Fisher & Paykel Healthcare, they dominate humidified oxygen in hospitals. They really don't have any competitors. They invest heavily in R&D. The business is growing strongly, but the stock fell over the period. Goodman Group completed a capital raising last year to reach a position of no debt, an extremely well-run business, with many opportunities globally, but it was down. REA still essentially holds a dominant position in what they do. I'm not sure how -- it's really a marketplace, it's difficult to see how AI can disrupt a marketplace like that, but it's had a significant pullback.

Robert Freeman

executive
#19

Auckland Airport is a monopoly asset, and it's down 10%. TechOne is an incredible company with earnings growing in the mid-teens, and it's rolling out its business where it's now getting great traction in the U.K., which is a much bigger market. It's well run, has no debt, but the stock was down 10%. I could go through this whole list, and carsales is another one — CAR group — with lots of opportunity to grow in South America. It has a dominant position in Australia, but the stock was down 13%. So I've just covered more than half the portfolio, and many of these companies continue to perform well. And we did trim some of these at the top. Harry Hindsight might say, well, maybe you should have exited, but we said we'd be a long-term investor in quality businesses, but it's been a tough year for all these stocks. But we want to look behind these businesses and continue to hold where we see a good opportunity. So there's been really no catastrophic failures in any of the companies. Most of it's been a valuation issue as such. Happy to take any questions on those at the end. So if you look at the recent activity, we ended up exiting — we had a small balance in NAB and Westpac.

Robert Freeman

executive
#20

Those were just minor positions. We got out of them. Equity trustees is out of the portfolio, and we did some trimming further up in names like Gentrack, Netwealth, Wesfarmers, HUB and Goodman Group. We've been adding to a few stocks where we're now seeing some softness, such as EVT. Woolworths struck us as good value at around $26, $27. So we built that position up. We've taken a small bite of Xero. We've added to Woodside. At current prices, we reckon the dividend yield there is pretty attractive. And Gentrack had a significant pullback from the level where we trimmed it, really only 6 to 12 months ago, and we've now been buying some of that back. We also saw some weakness in Nanosonics. We took a small starting position there, and likewise in peXA, given that they're beginning to see some success in the U.K. banking sector. So both of those are just small starting positions within the portfolio. So on we go. Our top 20 is there. And as you can see, we generally take a long-term approach with these companies. And perhaps we'll just move on to the next slide, which covers the entire portfolio.

Robert Freeman

executive
#21

We also have to be able to examine these holdings and determine that in our view they are well-managed businesses, with the capacity to increase earnings and solid positions in their markets — and we continuously apply that criterion to the stocks held in the portfolio. Yet the way we go about it is quite narrow in style. Should our style fall out of favor while other approaches come into favor, that produces this volatility, but we remain committed to staying true to the method we told investors we would use for AMCIL. Turning to the outlook, the market still appears to us somewhat full when measured against long-term metrics. We became somewhat more defensive 12 months ago by holding cash. In hindsight, putting all of that cash into gold would probably have been the better move, but the cash was there. What we are beginning to do now is act on particular opportunities we are seeing as quality stocks are sold off, and a couple of those have shown up over the last couple of weeks, letting us put that cash to work. For the moment, our position is that we will stick with our approach. There are always ways in which we can do things better.

Robert Freeman

executive
#22

And we're giving a lot more thought to whether we ought to be seizing more of the shorter-term opportunities when they appear — we should have moved faster on CSL. But our method of finding — and we want to be able to claim that we hold good quality companies — hasn't changed. So with that said, I think it's best to open things up for questions. And once again, it is disappointing, the 1-year number, and how it's affected every one of the numbers throughout. But we want to stay with our process of owning good quality companies. Over to questions, Geoff.

Geoffrey Driver

executive
#23

All right. Thank you, Mark. As a quick reminder, you’re able to submit a question through the webcast by using the tab located at the bottom of the screen. There’s one question I have here, and it actually combines a few questions regarding WiseTech. Could you comment on which main holdings account for the $34 million capital loss for the year? Did that include WiseTech? Also, why does AMCIL continue to hold a position in the company? At yesterday’s AFIC briefing, we heard very sound reasons—poor corporate governance and high debt—for why AFIC exited the position.

Robert Freeman

executive
#24

I think I addressed part of this in the presentation — the reason we keep a modest stake. When a company isn't performing the way you'd like, you've got options: you can bail out and sell the shares, and there are all sorts of reasons for doing so. In AMCIL's case, we felt we were able to keep a somewhat larger holding, while still engaging with the company — and we have raised corporate governance matters and similar issues with them. We believe the underlying product remains quite compelling, and that's why we've kept a small position.

Geoffrey Driver

executive
#25

There's a question here regarding CSL, which experienced a notable decline — it was a major holding. Has that caused many LICs to lead — or rather, has it led to LICs being displaced by ETFs?

Robert Freeman

executive
#26

Well, look, I'm not convinced a single stock really moves the needle. As we mentioned earlier, ETFs are expanding within the market, and the fact that LICs trade at discounts isn't anything new. It's occurred previously. What's interesting is that across all the other stretches over the last 30 years, we've been trading at a discount. In fact, that has tended to come ahead of a market correction. So it usually shows up when the market is running hot, with people pursuing other opportunities — mid- to small-cap mining stocks at the moment, for example — and we generally get left behind. That's LICs as a group. We've observed that pattern. Yet once a market correction arrives, the market then turns its attention back to the traditional LICs, and often we hold up, or there are usually solid dividend flows even through difficult periods. We tend to carry more conservative stocks, and then they tend to trade at a premium. So at this point the cycle is repeating itself. But let's see where things go from here.

Geoffrey Driver

executive
#27

I believe you're correct there, Mark. LIC products bring a distinct characteristic compared with ETFs. So it's important for people to grasp and appreciate that, especially in relation to that point.

Robert Freeman

executive
#28

Yes. I suppose we keep making the case that we are conventional LICs. No outside manager is involved. No performance fees are being taken, and that is in comparison with the method, at a fairly low cost.

Geoffrey Driver

executive
#29

There's a question I have regarding how much directors and staff own. I mean, I ran the figures pretty quickly here. From the annual report, staff and directors hold roughly 3% of the ownership, and former directors would be at nearly 20%. So combining those two groups, that's about 25% held by people who've been closely tied to AMCIL, and have we seen any selling — any major selling — from those departing directors? Given how recent the date is, is there any worry that local sales of the target vehicle for ARB products are declining, or that other models, like the BYD Shark, are growing more popular? Are those alternative vehicles less likely to be accessorized, even though ARB offers suitable products for them?

Robert Freeman

executive
#30

Yes. So that is a great question, and it's the one I still have outstanding. Right now I remain comfortable, because my feeling is that the folks purchasing the BYD Shark aren't the same folks who'd purchase conventional petrol or diesel engines, and we'll be adding ARB products through them. So if you -- your typical ARB owner of those kinds of vehicles usually wants to tow something, something heavy, the BYD Shark, if you attempt to tow something heavy, would likely run out of battery in roughly 10 minutes, or if you want to put heavy loading on the back of it. Again, that drains the battery considerably. So at this point, it's something we need to watch really closely, but I think that segment isn't the buyers of ARB products. I think purchasers of ARB products are sticking with traditional vehicles in that area. At the same time, we had a lot of confidence with the growth that the company was achieving out of the U.S. So I remember that they were able to buy into that U.S. business, they paid, I think, $30 million, an unbelievable deal to get into that footprint of about 50 stores.

Robert Freeman

executive
#31

I'd say the major upside going forward is gradually converting those locations and increasing the share of their own merchandise. That's how it works in Australia — the vast majority of goods sold through ARB shops are their own brand. That produces a tremendous margin improvement, and for the company in the U.S. that prospect is substantial. And if they manage to nail that, they could perhaps expand the store count down the road, since the American market is enormous. It's enormous for 4-wheel driving and every activity surrounding it. So right now, the business isn't moving in a straight line. This half they've faced some headwinds related to currency. OEMs may have given them guidance pointing to a stronger outlook than what has materialized near term. There are always some ups and downs, but overall, nobody anywhere does what ARB does when it comes to the R&D, the products they're building, the specialization they bring. They carry no debt, and there's meaningful opportunity. So at the moment we're staying with the story, though it's certainly an excellent question.

Geoffrey Driver

executive
#32

Moving to Mark's question: given that the valuation metric has improved, will management be raising our stake in TechnologyOne, especially since our cost base is probably higher than the present share price?

Robert Freeman

executive
#33

Yeah, so to address that — the share price right now sits well above what we paid. Our entry was roughly $17, so it's worked out really well for us. It climbed all the way up to $40, and we trimmed our position several times as it rose. At this point it's pulled back amid the broader anxiety surrounding structured compounders and tech. So the valuation is now reaching a level that, in our view, is beginning to look appealing once more for adding to the position. We've added a small amount, though we're monitoring it closely, since we believe this company has fairly robust growth in front of it.

Geoffrey Driver

executive
#34

Thanks, Mark. I’ll actually direct this question to Andrew so you can have a break. Has the recent share buyback delivered the outcome that was expected? Is there any information on the buyback cost per share? Would there be any merit in paying special dividends rather than going to the market for a share buyback?

Andrew J. Porter

executive
#35

Thanks. So did it deliver what was expected? Well, the reason we did it was that market conditions justified it, and the shares were trading at discounts. That certainly still took place. The cost per share — it's in the interim report — was $1.06, which was the average cost of the buyback. And those shares had been issued at $1.11. So we managed to buy shares back at a price below what they were issued at. That comes down to the market and how the AMCIL share price performed. So as for whether the buyback itself helped narrow the discount from 15% to 10%, it's very hard to say if that's what happened. History would suggest. On average, the impact isn't that great, but those are the figures. AMCIL has been paying special dividends. It did pay one at the end of the 2024 year. It has a track record of paying special dividends. And special dividends are one way of getting franking credits back to shareholders that we've realized, particularly through capital gains when we exit a position in the portfolio. An on-market share buyback won't let us distribute those franked dividends. So it isn't a matter of either or — it's a matter of both.

Andrew J. Porter

executive
#36

So in the event that franking credits are available to us, the Board will consider paying a special dividend when it makes sense to do so. And should market conditions be right, they would also examine an on-market buyback.

Geoffrey Driver

executive
#37

And Andrew, I think, considering how things have gone lately, the Board has—like I mentioned—a track record of issuing special dividends across the past few years, and while those can differ, that track record does exist. Right?

Andrew J. Porter

executive
#38

You've got that right.

Geoffrey Driver

executive
#39

Okay, coming back to CSL — since it affects performance so much. I suppose what we're really asking is: how should we evaluate whether CSL fits properly within the portfolio? And do we bring in people from beyond the investment industry, so to speak, to help us think through how we invest in CSL?

Robert Freeman

executive
#40

And I believe I did bring up the matter concerning 112, which represented a big outlay for the business and ended up being unsuccessful, and they burned a considerable amount of capital in the process. So clearly, what you've witnessed from the company is a pullback in how much they will devote to R&D. Looking ahead, it has been a major drag on performance. Yet ultimately, they continue to make products that customers want and need in order to survive, essentially. And it's in therapeutic areas where demand remains unmet, and they keep discovering more and more patients suffering from these conditions. As such, the market opportunity remains substantial, and that's the reason we still believe there could be growth — getting these products out of plasma is difficult and intricate. So there are a few rivals, but CSL is the bigger one, and we believe it holds benefits as a result, especially when it comes to plasma collection. So I'd put it this way: the market was overly hopeful about the capacity to restore margins to prior levels. But it does appear sensible that they ought still to expand over time, perhaps in the high single-digit range, which remains extremely strong growth.

Geoffrey Driver

executive
#41

Should we think about holding a modest gold allocation within the trading portfolio? Naturally, if it were going to pay off, that step should have been taken earlier, but the real issue here is one of principle.

Robert Freeman

executive
#42

Yes. Look, in principle, obviously, the answer would be yes. And so we've discussed how, even though our emphasis perhaps lies on quality compounders, you can still uncover opportunities—if we believe a sector is going to run, what's the best player in that segment, and should we take a shorter-term position? And so those kinds of reflections, we've certainly had on that. We get a bit of exposure to resources. We've had a good holding in ALS. There's still a lot of the minerals testing. But clearly, that hasn't sort of made up for the strength that we've seen in the gold stocks.

Geoffrey Driver

executive
#43

Thanks, Mark. I’ve got a question about the broader LIC sector. It looks like LICs that perform poorly tend to take the same route: raising dividends, paying special dividends, and buying back shares. So I’d ask how successful that really is, apart from giving investors in liquid LICs a chance to exit—could those funds have been put to better use?

Robert Freeman

executive
#44

Yes, that's a really good question. So, just on, I suppose, why we do that. It isn't really tied to, like, any performance. What we take a view on is that some of the LICs do hold some franking credits for a rainy day. Just a general view, if you go beyond that, they belong to the shareholders. So you — so you pay them out. And that — I mean, we have that policy, whether we were talking about this 12 months ago, when we were hit on all our figures, we still talked about what's our excess franking credits to get them out to shareholders. So I don't think that's a matter of performance. I think it's just — we think that's a good practice to get the franking credits out if you've got excess than what you believe. And on buybacks, I think it's been — our decision on buybacks is really more around where we're trading against to NTA. And if we're sustaining a DRP and the people that tend to go in DRPs tend to generally be the same one, sometimes at a premium. You have to remember, it was only 3 years ago during COVID, that many LICs were trading at premiums.

Robert Freeman

executive
#45

So we generally keep the DRP switched on, and clearly a lot of shareholders have told us, well, if you're issuing stock at a discount, why not offset it by buying back at that level. That strikes us as sensible. And so we've been carrying out these buybacks to offset the diluting effect of the DRP. If we were trading near NTA, then I mean that's a matter for the Board, but I think it's fairly fair to say we wouldn't be buying back stock in that situation.

Andrew J. Porter

executive
#46

And when you repurchase, what you're really doing is acquiring shares or a portfolio you favor at a price below what it would take to purchase them in the open market.

Robert Freeman

executive
#47

Yes. But in principle, we'd prefer not to be doing this, because if we were trading around NTA, we wouldn't be doing it — we simply wouldn't. And we still have the facility within the funds to go out and buy stocks that we like regardless. So that isn't something that's preventing us from going out and making use of those. And once again, if months ago performance was good, and we're trading at a discount, we still look to buy back. So this isn't a performance decision. It's about where the stock is trading in the market and looking to neutralize a DRP.

Geoffrey Driver

executive
#48

Do you think LICs might deliver greater value for investors and grow more relevant as the market potentially becomes more passive? How are you working to help the market, especially younger people, grasp that?

Robert Freeman

executive
#49

Yes. I think -- well, I'll say a bit more about our group as traditional LICs. So these are generally low cost, and you could say they're similar to an ETF. But they had different characteristics and different ways of going about it. So I think it's important that we try to understand, or educate the market, that we are low cost like ETS, that we are an alternative to an ETF. But there are certain characteristics that come with being in a company structure, such as consistent dividend pays. We don't have flows in and out. I mean, the growth in ETF, we haven't seen it tested in a while on a decent downturn, given the amount of money that's pouring into them. We can buy when we want to, we can sell when we want to. So it's just a matter of trying to differentiate the product. But the key thing is that -- and so -- I mean a lot of people like the transparency that comes from being an LIC as well. So I think there's -- we are trying to beef up our education of the market. I've been doing more webcast and podcast, sorry, to talk about this and try and expand the understanding of LIC, traditional LIC.

Geoffrey Driver

executive
#50

Yes. And a number of those podcasts specifically aim at the younger generation, as you're well aware — plenty of people in that demographic would turn to podcasts instead of actually searching online for things too. So those are the ones we're concentrating on. We also have Suzanne, our business development manager, who came on board, as Mark mentioned earlier, and we're definitely doing considerably more marketing aimed at financial advisers, which has really only got underway during the last 6 months. So hopefully we'll reap the rewards from that across the coming 12 to 18 months. Do you think you picked stocks that were overpriced with very high IP? Some of them have no earnings whatsoever. How do you factor that into the portfolio context?

Robert Freeman

executive
#51

Yes, I can see — I mean, the question is visible to me. Actually, most of those Life36 stocks, in fact I believe nearly all of them apart from Life36 <<inaudible>>, are profitable businesses with solid balance sheets. And I think what you're getting at is the P/Es. Those aren't the P/Es. I mean, take carsales, for instance — you're implying a P/E of 49. On a prospective basis right now, we'd probably put it at around 24x. So I can see several of the P/Es you've cited there that differ greatly; I'm glad to take that question offline if you'd like to check in, because some of these P/Es — pretty much all of them — aren't the figures that we have — they're vastly different. So look, valuations matter. Obviously we take them into account when purchasing. After that, we tend to hold. But as I mentioned, aside from one, you've named a great many companies, and all of them are profitable businesses growing strongly.

Geoffrey Driver

executive
#52

Alright. A quick reminder that you’re able to submit a question through the webcast by using the tab located at the bottom of your screen. Here’s a question about CSL — it’s really more about the level of confidence in management, considering the $20 billion we spent on that before acquisition?

Robert Freeman

executive
#53

Right, so clearly the CEO who held the role at the time of that decision has since left the company. A new CEO came in, and they held a strategy day late last year, where they again discussed a refreshed approach to R&D. They acknowledge that the acquisition was a poor one. That can't be undone now. What you'd hope is that they avoid making another one. My sense is they won't. I believe their attention is now firmly on the core business. As for the plan to spin out Seqirus, we found ourselves somewhat puzzled by it, but they moved away from that idea. And once more, I think they're sort of getting — the message we've received is that they're just getting there. And strengthening the core business. That focus appeals to me. There are, I think, questions about how much the cost base has risen over time, given the way they were running a number of R&D projects and so on. So it feels to me like the company is now very concentrated on the core. And when we — typically when we observe that, we see improved results from businesses, though I'm not certain what will happen in this particular result.

Robert Freeman

executive
#54

However, as we look ahead across the coming years, usually, I suppose, when a company reaches a point where it decides to get the core operating well—to concentrate on that—you tend to see considerably improved results.

Geoffrey Driver

executive
#55

On the question of whether the DRP will be neutralized — that's something we're looking at closely.

Robert Freeman

executive
#56

Well, look, it really hinges on how the stock is trading relative to its NTA. If it's at a sufficiently large discount, and we believe doing that would add value, then we will — if it makes sense, we'll go ahead with it. If for some reason it closes, then we won't proceed. So it's really more about what we're seeing in the market.

Geoffrey Driver

executive
#57

Alright, Mark, I don’t have any questions at this point. I’ve noticed the viewer count is beginning to fall off, so maybe we should wrap up the presentation here.

Robert Freeman

executive
#58

All right, thanks to all of you for joining. As I mentioned, we're strongly committed to enhancing returns. This has been a deeply disappointing year, though we remain believers in owning high-quality businesses over the long run. There are some lessons to draw from it. And we are — I'd say we'd still maintain a balanced portfolio through time. And to hold equities spanning a variety of sectors. With that, I'll hand things back to the moderator. Thank you.

Operator

operator
#59

Thanks, everyone. That brings today's webinar to a close. We appreciate you taking part, and you're welcome to drop off the lines now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AMCIL Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to AMCIL Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in AMCIL Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.